13F Holdings
中文EN

XENE Xenon Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1582313 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-40.0%
TTM EPS YoY-20.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-50.3%
ROA-47.4%
ROIC (approx.)-48.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets4.5%
Debt / equity0.00x
Current ratio21.19x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$7.50M$0$0$9.43M$18.44M
R&D expense$300.94M$210.39M$167.51M$105.77M$75.46M
SG&A expense$79.63M$68.90M$46.54M$32.81M$21.97M
Operating income-$373.07M-$279.30M-$214.05M-$129.14M-$78.99M
Pretax income-$344.89M-$238.42M-$182.69M-$125.25M-$78.89M
Income tax$1.02M-$4.09M-$292,000$118,000-$6,000
Net income-$345.91M-$234.33M-$182.39M-$125.37M-$78.88M
EBITDA-$370.53M-$276.74M-$211.99M-$127.74M-$78.09M
EPS (basic)-4.36-3.01-2.73-2.06-1.77
EPS (diluted)-4.36-3.01-2.73-2.06-1.77
Weighted avg. shares (diluted)79.25M77.89M66.89M60.54M43.63M
Balance sheet
Cash & equivalents$199.16M$142.71M$148.64M$57.24M$175.69M
Short-term investments$349.72M$484.19M$489.44M$534.85M$376.09M
Receivables—$1.47M$874,000$986,000$2.77M
Current assets$560.65M$635.26M$644.96M$600.30M$559.02M
PP&E, net$8.72M$10.28M$9.65M$6.50M$4.47M
Total assets$633.16M$798.14M$964.80M$754.15M$572.01M
Current liabilities$41.79M$35.59M$27.27M$22.70M$14.32M
Total liabilities$51.40M$43.24M$36.88M$32.65M$21.97M
Shareholders' equity$581.76M$754.90M$927.92M$721.50M$550.03M
Shares outstanding80.01M76.42M75.37M62.59M51.63M
Cash flow statement
Operating cash flow-$279.12M-$181.39M-$151.11M-$101.03M-$69.50M
Capital expenditure$799,000$3.08M$5.62M$2.89M$2.05M
Free cash flow-$279.92M-$184.46M-$156.73M-$103.92M-$71.55M
Investing cash flow$218.00M$165.00M-$111.39M-$293.40M-$246.77M
Financing cash flow$117.11M$12.13M$353.52M$278.47M$447.54M
Depreciation & amortization$2.54M$2.56M$2.06M$1.41M$906,000
Stock-based compensation$53.71M$50.72M$32.37M$20.38M$10.02M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.